These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 19604043

  • 1. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
    Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte Ad, Katlama C, Eg Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD, EuroSIDA Study Group.
    J Infect Dis; 2009 Sep 01; 200(5):687-97. PubMed ID: 19604043
    [Abstract] [Full Text] [Related]

  • 2. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine.
    Bocket L, Yazdanpanah Y, Ajana F, Gerard Y, Viget N, Goffard A, Alcaraz I, Wattré P, Mouton Y.
    J Antimicrob Chemother; 2004 Jan 01; 53(1):89-94. PubMed ID: 14645320
    [Abstract] [Full Text] [Related]

  • 3. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.
    Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P, Ledergerber B, Holkmann C, Staszewski S, Lundgren JD, EuroSIDA Study Group.
    Antivir Ther; 2005 Jan 01; 10(7):791-802. PubMed ID: 16312176
    [Abstract] [Full Text] [Related]

  • 4. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
    Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G.
    Antivir Ther; 2006 Jan 01; 11(2):233-43. PubMed ID: 16640104
    [Abstract] [Full Text] [Related]

  • 5. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D, Schapiro JM, Lanier ER, Gradstein S, Gottesman G, Kedem E, Einhorn M, Grisaru-Soen G, Ofir M, Engelhard D, Grossman Z.
    Pediatr Infect Dis J; 2006 Nov 01; 25(11):1049-56. PubMed ID: 17072129
    [Abstract] [Full Text] [Related]

  • 6. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.
    Cozzi-Lepri A, Paredes, Phillips AN, Clotet B, Kjaer J, Von Wyl V, Kronborg G, Castagna A, Bogner JR, Lundgren JD, EuroSIDA in EuroCoord.
    HIV Med; 2012 Jan 01; 13(1):62-72. PubMed ID: 21848790
    [Abstract] [Full Text] [Related]

  • 7. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
    Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD, EuroSIDA Study Group.
    AIDS; 2007 Mar 30; 21(6):721-32. PubMed ID: 17413693
    [Abstract] [Full Text] [Related]

  • 8. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens.
    Maggiolo F, Ripamonti D, Torti C, Arici C, Antinori A, Quiros-Roldan E, Minoli L, Sighinolfi L, Nasta P, Suter F, MASTER Data Base Cohort.
    Antivir Ther; 2006 Mar 30; 11(7):923-9. PubMed ID: 17302255
    [Abstract] [Full Text] [Related]

  • 9. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A, Porten K, Fampou-Toundji JC, Galli L, Mougnutou R, Buard V, Kfutwah A, Vessière A, Rousset D, Teck R, Calmy A, Ciaffi L, Lazzarin A, Gianotti N.
    Antivir Ther; 2009 Mar 30; 14(3):339-47. PubMed ID: 19474468
    [Abstract] [Full Text] [Related]

  • 10. Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy.
    Mouroux M, Descamps D, Izopet J, Yvon A, Delaugerre C, Matheron S, Coutellier A, Valantin MA, Bonmarchand M, Agut H, Massip P, Costagliola D, Katlama C, Brun-Vezinet F, Calvez V.
    Antivir Ther; 2001 Sep 30; 6(3):179-83. PubMed ID: 11808752
    [Abstract] [Full Text] [Related]

  • 11. Foscarnet salvage therapy efficacy is associated with the presence of thymidine-associated mutations (TAMs) in HIV-infected patients.
    Charpentier C, Laureillard D, Sodqi M, Si-Mohamed A, Karmochkine M, Bélec L, Weiss L, Piketty C.
    J Clin Virol; 2008 Oct 30; 43(2):212-5. PubMed ID: 18760662
    [Abstract] [Full Text] [Related]

  • 12. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
    Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ive P, Botes ME, Wellington M, Osibogun A, Stevens WS, Rinke de Wit TF, Schuurman R, PharmAccess African Studies to Evaluate Resistance (PASER).
    Clin Infect Dis; 2012 Jun 30; 54(11):1660-9. PubMed ID: 22474222
    [Abstract] [Full Text] [Related]

  • 13. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
    Simcock M, Sendi P, Ledergerber B, Keller T, Schüpbach J, Battegay M, Günthard HF, Swiss HIV Cohort Study.
    Antivir Ther; 2006 Jun 30; 11(3):305-14. PubMed ID: 16759046
    [Abstract] [Full Text] [Related]

  • 14. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, Chantratita W.
    J Clin Virol; 2008 Apr 30; 41(4):310-3. PubMed ID: 18316243
    [Abstract] [Full Text] [Related]

  • 15. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ, Kannangai R, Verghese VP, Pulimood SA, Rupali P, Sridharan G, Grant P, Pillay D, Abraham OC.
    Indian J Med Microbiol; 2009 Apr 30; 27(3):231-6. PubMed ID: 19584504
    [Abstract] [Full Text] [Related]

  • 16. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
    Jaspan HB, Berrisford AE, Boulle AM.
    Pediatr Infect Dis J; 2008 Nov 30; 27(11):993-8. PubMed ID: 18818556
    [Abstract] [Full Text] [Related]

  • 17. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
    Lohse N, Jørgensen LB, Kronborg G, Møller A, Kvinesdal B, Sørensen HT, Obel N, Gerstoft J, Danish HIV Cohort Study.
    Antivir Ther; 2007 Nov 30; 12(6):909-17. PubMed ID: 17926645
    [Abstract] [Full Text] [Related]

  • 18. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
    Flandre P, Descamps D, Joly V, Meiffrédy V, Tamalet C, Izopet J, Aboulker JP, Brun-Vézinet F.
    Antivir Ther; 2003 Feb 30; 8(1):65-72. PubMed ID: 12713066
    [Abstract] [Full Text] [Related]

  • 19. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.
    Lafeuillade A, Poggi C, Hittinger G, Chadapaud S.
    HIV Med; 2001 Oct 30; 2(4):231-5. PubMed ID: 11737402
    [Abstract] [Full Text] [Related]

  • 20. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.
    Justice AC, Stein DS, Fusco GP, Sherrill BH, Fusco JS, Danehower SC, Becker SL, Hansen NI, Graham NM, CHORUS Program Team.
    J Clin Epidemiol; 2004 Jan 30; 57(1):89-97. PubMed ID: 15019015
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.